论文部分内容阅读
研究他莫昔芬和甲孕酮对人卵巢癌细胞增殖和凋亡的影响。方法 :用不同剂量的他莫昔芬和甲孕酮与人卵巢癌细胞系HO 891 0体外培养 96h ,用苔盼蓝活细胞拒染法计活细胞数 ,免疫组化SABC法检测癌细胞增殖核抗原 (PCNA)表达情况 ,DNA缺口原位末端标记方法 (TUNEL)检测细胞凋亡情况。结果 :他莫昔芬和甲孕酮在 0 1、1、1 0 μmol均可使HO 891 0活细胞数显著减少 (P <0 0 1 ) ;通过诱导细胞凋亡抑制卵巢癌细胞生长 ,呈剂量依赖性。低浓度 (≤ 1 μmol L)的他莫昔芬对PCNA表达的影响无统计学意义 (P >0 0 5 ) ,而高剂量 ( 1 0 μmol L)时可显著降低PCNA表达 (P <0 0 5 )。甲孕酮在 0 1、1、1 0 μmol时均明显降低PCNA表达 (P <0 0 1 ) ;他莫昔芬与甲孕酮均可诱导HO 891 0细胞凋亡 (P <0 0 1 ) ,且呈剂量依赖性 ,甲孕酮诱导凋亡程度显著高于他莫昔芬 (P <0 0 1 )。结论 :他莫昔芬在低剂量时对细胞增殖和抑制作用较弱 ,高剂量时不但可抑制卵巢癌细胞增殖 ,且可诱导细胞凋亡 ,但均弱于甲孕酮 ,本研究为卵巢癌的内分泌治疗提供实验依据
To investigate the effects of tamoxifen and megestrol on the proliferation and apoptosis of human ovarian cancer cells. Methods: Toxicities of tamoxifen and megestrol with human ovarian cancer cell line HO 891 0 were cultured in vitro for 96h. The number of viable cells was counted by trypan blue exclusion method. The proliferation of cancer cells was detected by immunohistochemical SABC method The expression of nuclear antigen (PCNA) and DNA nick end labeling (TUNEL) were used to detect the cell apoptosis. Results: Tumor cells treated with tamoxifen and medroxyprogesterone acetate at 0.1, 1, and 1 μmol·L -1 significantly decreased the number of viable cells (P <0.01) and inhibited the growth of ovarian cancer cells by inducing apoptosis Dose-dependent. Tamoxifen at a low concentration (≤1 μmol L) had no significant effect on PCNA expression (P 0 05), but decreased PCNA expression at a high dose (100 μmol L) (P 0 0 0 5). Medroxyprogesterone acetate decreased the expression of PCNA significantly (P <0.01), and both tamoxifen and medroxyphene could induce the apoptosis of HO8910 cells (P <0.01) , And in a dose-dependent manner, progesterone-induced apoptosis was significantly higher than tamoxifen (P <0.01). CONCLUSION: Tamoxifen has a weak effect on proliferation and inhibition of cells at low dose. It not only inhibits the proliferation of ovarian cancer cells at high dose, but also induces apoptosis, but both are weaker than that of progesterone. In this study, ovarian cancer Endocrine therapy to provide experimental evidence